How Zepbound differs from Mounjaro — and what that means for UK patients

You've seen Zepbound everywhere, here's why your pharmacy has never heard of it

Imagine you've been reading about tirzepatide on a US health site, or watching someone's weight-loss journey on social media. The name Zepbound appears constantly. Then you search for it on a UK pharmacy site and nothing comes up. That gap is not a stock problem, it is a branding decision by Eli Lilly. When the company sought approval for tirzepatide as a weight-management medicine, it registered Zepbound as the US brand with the FDA and Mounjaro as the name for markets including the UK and European Union. The molecule, the mechanism and the clinical evidence are identical. The label is different.

This matters practically because any seller in the UK claiming to supply Zepbound is either describing something that does not legally exist here or is sourcing medicines outside the licensed UK supply chain, neither situation you want for a prescription-only injectable. The MHRA, which licenses medicines in the UK, has not granted a marketing authorisation to a product called Zepbound. Full stop. If you want tirzepatide in the UK, the licensed form is Mounjaro, dispensed through GPhC-registered pharmacies against a valid UK prescription.

A question our prescribers hear most weeks is some version of: "Can I get Zepbound instead, is it stronger?" The answer is no, and no. Same strength range, same injection device, same titration schedule starting at 2.5 mg. The only difference is the label on the box.

How the science behind the name stacks up against other UK-licensed options

Understanding what tirzepatide actually does helps explain why patients seek it out under any name. It targets two receptors at once (GIP and GLP-1) both involved in appetite regulation and blood-sugar control. Semaglutide, the active ingredient in Wegovy, targets GLP-1 alone. That dual action is why tirzepatide is described as a different class of medicine, not just a newer iteration of the same approach. You can read more about how emerging molecules compare to tirzepatide as research continues to move quickly.

In the SURMOUNT-1 trial, involving 2,539 adults with obesity, participants on the 15 mg maintenance dose achieved an average body-weight reduction of around 20–21% over 72 weeks, figures that are cited in NICE's appraisal of tirzepatide (TA1026) as the basis for recommending it in England. In the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4 mg over the same duration. These are the numbers behind the interest, and they belong to the medicine regardless of which country's brand name you search for.

Wegovy (semaglutide) is the other injectable licensed in the UK for weight management, with its own strong trial evidence from the STEP programme. Which suits a particular person is a clinical question, not one a comparison article can answer definitively. The weight-loss treatment overview covers both options if you want to read them side by side.

What is actually licensed for weight management in the UK, and how to access it safely

The two medicines with UK marketing authorisations for weight management are Mounjaro (tirzepatide) and Wegovy (semaglutide). Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Wegovy carries broadly similar eligibility criteria.

Neither medicine can be supplied in the UK without a valid prescription. That clinical step is not a formality. A prescriber checks for contraindications, reviews your medical history, considers other medicines you take, and decides the appropriate starting point. Patients who try to source tirzepatide labelled as Zepbound from overseas sellers or unverified online sources are bypassing all of that, and the MHRA has warned repeatedly about fake weight-loss pens circulating online, some containing insulin rather than the labelled medicine. It is worth reading the MHRA's Yellow Card scheme if you want to understand how to report suspect sellers.

There is also the question of cost context. Eli Lilly raised Mounjaro's UK list price in September 2025, with the highest-dose pen's list price reported to have risen to around £330 per four-week supply. Private provider prices vary around that figure by dose and provider. The background to that price change explains what drove it and what it means for people accessing treatment privately. The different names tirzepatide goes by across markets is a separate piece of context worth having if you are researching across US and UK sources simultaneously.

Tirzepatide's various brand names can create real confusion for anyone researching across borders. The full picture of tirzepatide brand names and the direct comparison of Zepbound and Mounjaro cover that ground in more detail if you want it.

If you are considering tirzepatide and want to find out whether you are clinically suitable, the right starting point is a free consultation with a prescriber who can review your history properly. That is what a legitimate, regulated route looks like, and it is how the clinical team at nume approaches every assessment.